-
Bazedoxifene: A Translational Strategy for ER Modulation
2026-09-29
Bazedoxifene is more than a catalog compound: it is a useful translational probe for studying how tissue-selective estrogen receptor modulation can preserve skeletal outcomes while limiting mammary and endometrial stimulation. This thought-leadership article connects receptor pharmacology, cell and animal validation, clinical evidence, experimental design, and competitive positioning. It also defines where the evidence is mature, where caution is required, and how researchers can build more decision-ready osteoporosis treatment research around a selective estrogen receptor modulator.
-
Lipo3K Transfection Reagent for Ferroptosis Studies
2026-09-29
Lipo3K Transfection Reagent is a cationic lipid transfection reagent for DNA, siRNA, and mRNA delivery across adherent, suspension, and difficult-to-transfect cells. Its low-toxicity workflow can support gene expression studies and RNA interference research, including experiments that investigate the OTUD3–SLC7A11 pathway described in clear cell renal cell carcinoma.
-
Bazedoxifene and IL-6/GP130 Signaling in Cancer
2026-09-28
Shi and colleagues review evidence that bazedoxifene, a selective estrogen receptor modulator, can also interfere with IL-6/GP130 signaling associated with tumor progression. Their synthesis supports further mechanistic and preclinical investigation, while underscoring that this repurposing rationale is not evidence of established cancer treatment efficacy.
-
Bradykinin B2 Receptors and Ileal Peristalsis
2026-09-27
Chan and Rudd used selective kinin-receptor agonists and antagonists to show that bradykinin B2 receptor activation raises the pressure threshold for peristalsis in isolated guinea pig ileum. The results identify an inhibitory modulatory pathway in this preparation while distinguishing it from B1-receptor signaling and from the facilitatory effects of serotonin.
-
CD38 CAR Binder Structures and Affinity Tuning
2026-09-26
Cheng and colleagues show that two CD38 CAR binders, RP02 and 028, engage distinct antigen surfaces and differ in their effects on CD38 cyclase activity. Their structure-guided analysis further indicates that attenuating 028 affinity can reduce CAR-T fratricide while retaining tumor-cell cytotoxicity, offering a mechanistic approach to balancing activity and selectivity.
-
Imipramine Workflows for Autophagy and Apoptosis
2026-09-26
Use Imipramine to build complementary autophagy and apoptosis experiments in glioma and leukemia models, while separating cell-based responses from transporter-binding potency. A ceramide-focused fish-virus study offers a useful experimental-design precedent—not evidence that Imipramine is antiviral or acts through ceramides.
-
E-64d in Cell-Death Screens: Read Death, Not Growth
2026-09-25
E-64d is a membrane-permeable cysteine protease inhibitor, but its effects in cell-death experiments are easiest to interpret when growth and death are measured separately. This article connects E-64d perturbation design to a time-resolved functional-genomics framework, clarifying what inhibitor responses can—and cannot—show.
-
Tin Mesoporphyrin IX as a Causal HO Probe
2026-09-25
Tin Mesoporphyrin IX (chloride) offers a way to test whether heme oxygenase activity contributes to redox-sensitive phenotypes, rather than merely tracking with them. This article connects its biochemical profile to practical assay choices in HBV and metabolic disease research while defining the limits of pharmacological inference.
-
Kozak Libraries Quantify Transgene Expression Effects
2026-09-24
Shukla and colleagues use a pooled Kozak sequence library to tune transgene abundance across an approximately 100-fold range, connecting sequence context to protein levels and cellular phenotypes. Their approach offers a heritable, library-compatible way to study how protein abundance interacts with coding variation, illustrated with ACE2-mediated viral entry and ACE2 and STIM1 variant panels.
-
DOPE for mRNA LNP Design and Endosomal Escape
2026-09-24
Learn how to use DOPE as a helper phospholipid when optimizing nucleic acid delivery, from stock preparation to cell-based readouts. A recent zwitterionic-lipid study offers a useful design lesson for improving endosomal escape—but DOPE and the study’s MeDZ lipid are not interchangeable.
-
Spiroplasma Entry into Drosophila S2 Cells
2026-09-23
Wei and colleagues established a Drosophila Schneider 2 cell model showing that Spiroplasma eriocheiris can invade, proliferate within, and damage insect-derived cells. Pharmacological and cytoskeletal perturbations implicated clathrin-mediated endocytosis, macropinocytosis, actin, myosin II, and microtubules, providing a mechanistic framework for studying a crustacean pathogen in an invertebrate cell system.
-
Bazedoxifene Workflows for ER and IL-6 Research
2026-09-23
Build reproducible Bazedoxifene assays that separate estrogen receptor pharmacology from emerging IL-6/GP130 pathway activity. This practical guide connects postmenopausal osteoporosis models, breast-cell assays, and oncology-focused signaling workflows with formulation and troubleshooting advice.
-
Cell Counting Kit-8 for Wound-Inflammation Models
2026-09-22
Use Cell Counting Kit-8 to separate compound-driven cytotoxicity from genuine anti-inflammatory activity in MRSA and wound-healing models. This practical cck8 workflow covers plate design, concentration selection, signal interpretation, interference controls, and validation strategies.
-
DDI2–NFE2L1 Signaling Protects From Ferroptosis
2026-09-21
The reference study identifies DDI2-mediated activation of NFE2L1 as an adaptive proteostasis circuit that limits ferroptosis after oxidative and lipid stress. Its combination of ubiquitylation-site proteomics, genetic perturbation, and pharmacological validation provides a framework for studying how proteasome remodeling influences ferroptotic vulnerability.
-
PX-478 2HCl for Hypoxia Research
2026-09-21
PX-478 2HCl provides a practical way to suppress HIF-1α and connect protein-level signaling with functional hypoxia phenotypes. This guide translates product specifications and prenatal hypoxia findings into reproducible cell, radiosensitization, and in vivo tumor ischemia workflows.